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The grade of recurrent in situ and invasive carcinoma occurring after treatment of pure ductal carcinoma in situ (DCIS) has been
compared with the grade of the original DCIS in 122 patients from four different centres (The Royal Marsden Hospitals, London and
Sutton, 57 patients; Guy’s Hospital, London, 19 patients; Nottingham City Hospital, 31 patients and The Royal Liverpool Hospital, 15
patients). The recurrent carcinoma was pure DCIS in 70 women (57%) and in 52 women (43%) invasive carcinoma was present,
which was associated with an in situ element in 43. In all, 19 patients developed a second recurrence (pure DCIS in 11 and invasive
with or without an in situ element in eight). The majority of invasive carcinomas followed high-grade DCIS. There was strong
agreement between the grade of the original DCIS and that of the recurrent DCIS (k¼0.679), which was the same in 95 of 113
patients (84%). The grade of the original DCIS showed only fair agreement with the grade of recurrent invasive carcinoma
(k¼0.241), although agreement was stronger with the pleomorphism score of the recurrent carcinoma (k¼0.396). There was
moderate agreement, in recurrent invasive lesions, between the grade of the DCIS and that of the associated invasive element
(k¼0.515). Other features that showed moderate or strong agreement between the original and recurrent DCIS were necrosis and
periductal inflammation. The similarity between the histological findings of the original and subsequent DCIS is consistent with the
concept that recurrent lesions represent regrowth of residual carcinoma. In addition, although agreement between the grade of the
original DCIS and that of any subsequent invasive carcinoma was only fair, there is no suggestion that low-grade DCIS lesions
progress to higher grade lesions or to the development of higher grade invasive carcinoma. This is in agreement with
immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions.
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The best treatment for ductal carcinoma in situ (DCIS) of the
breast has yet to be determined, although there is an increasing
body of evidence that radiotherapy is of benefit after wide local
excision (Julien et al, 2000; UK Coordinating Committee on Cancer
Research (UKCCCR) Ductal Carcinoma in situ Working Party,
2003). The increase in the number of cases diagnosed since the
introduction of mammographic screening has emphasised the
considerable diversity exhibited by these lesions. Several histo-
pathological classifications have been proposed during the past
two decades (Lagios et al, 1989; Holland et al, 1994; Poller et al,
1994; Silverstein et al, 1995, 1996; Scott et al, 1997; Sloane et al,
1998). These are all based primarily on nuclear morphology and
also, in some, on the presence or absence of necrosis or cell
polarisation. The histological type, together with the lesion size,
and, perhaps of most significance, the size of the margin of
clearance have been found to be the best determinants of the risk
of recurrence (Lagios et al, 1989; Poller and Ellis, 1995; Silverstein
et al, 1996, 1999; Bijker et al, 2001a; Douglas-Jones et al, 2002).
Approximately half of the recurrent lesions remain in situ, but half
show evidence of invasion. Owing to the potential for metastasis,
the latter are of considerable significance as the chance of
successful eradication of the disease may have been lost. In several
studies the incidence of recurrence, at least in the short term, has
been found to be higher following high-grade (poorly differ-
entiated) DCIS than following low-grade (well differentiated)
lesions (Lagios et al, 1989; Schwartz et al, 1992; Bellamy et al,
1993; Solin et al, 1993; Sneige et al, 1995; Silverstein et al, 1996;
Fisher et al, 1999). Moreover, in some studies, the incidence of an
invasive recurrence has been found to be higher after high-grade
DCIS than after low-grade lesions (Lagios et al, 1989; Bellamy et al,
1993). This suggests that more radical initial treatment may be
indicated for high-grade DCIS than for low-grade DCIS.
Histopathological studies of invasive carcinoma with an
associated in situ component have shown a close link between
the grade of the in situ and that of the invasive component
(Lampejo et al, 1994; Goldstein and Murphy, 1996; Gupta et al,
1997). Furthermore, the clinical outcome is related to the histology
of the DCIS. Those with a well-differentiated in situ component
associated with their invasive carcinoma have a more favourable
prognosis than patients with poorly differentiated lesions (Lam-
pejo et al, 1994; Gupta et al, 1997). Studies of recurrent in situ and
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have shown a high degree of correlation between the grades of the
original and recurrent tumours (Barnes et al, 2000; Bijker et al,
2001b). If recurrent lesions following pure DCIS are always of the
same grade, it can be argued that low-grade DCIS is not only less
likely to recur and to develop invasive disease but also that, if it
does recur, the chance of successful treatment is still there. If this
is so, such lesions could be managed in a less radical manner.
The present study was undertaken to try to establish the nature
of recurrent lesions, both in situ and invasive, occurring following
the treatment of pure DCIS.
MATERIALS AND METHODS
The files of patients treated for DCIS were reviewed and those in
whom a recurrent carcinoma had occurred after an interval of at
least 6 months from initial treatment were selected. The recurrent
lesions were within the ipsilateral residual breast or, in a few cases,
within the mastectomy scar. Only cases in which the slides of both
the primary and recurrent tumour were available for review were
included in the study. The 122 patients studied were seen and
treated at the Royal Marsden Hospital, London and Surrey (RMH)
(57 patients; initial diagnosis between 1975 and 1990), Guy’s
Hospital, London (Guy’s) (19 patients; initial diagnosis 1975–
1994), Nottingham City Hospital (NCH) (31 patients; initial
diagnosis 1975–1996) and the Royal Liverpool Hospital (RLH)
(15 patients; initial diagnosis 1982–1996). Preliminary findings
relating to some of the NCH patients have been included in
previous presentations (Barnes et al, 2000).
The age of the patients ranged from 24 to 81 years (Guy’s
patients, 24–81 years, median 54 years; RMH patients, 28–72
years, median 52 years; NCH patients, 29–75 years, median 52
years; RLH patients, 37–64 years, median 54 years). Treatment in
the majority of cases was surgical excision either alone or in
combination with adjuvant tamoxifen or radiotherapy or both. In a
minority, initial treatment was simple or radical mastectomy. The
time to first recurrence ranged from 6 to 177 months (Guy’s
patients, 18–177 months, median 69 months; RMH patients, 7–
125 months, median 39 months; NCH patients, 6 months–143
months, median 56 months; RLH patients, 12–180 months,
median 36 months).
The following features were recorded in the primary in situ
tumours: nuclear grade, architectural pattern, necrosis and
periductal fibrosis and inflammatory (lymphoplasmacytic) reac-
tion. In the recurrent lesions, the nuclear grade of the in situ
carcinoma and, in most cases, also the presence of necrosis, the
architectural pattern and periductal changes were noted, as was the
grade of the invasive lesion where present. The slides were
reviewed separately by two of the authors in all cases, and where
there was disagreement they were then studied together or in some
cases a third author was consulted.
The nuclear grade of the in situ lesions was based on the features
used in the United Kingdom National Health Service Breast
Screening Programme (UK NHSBSP) and the European Commis-
sion Working Group on Breast Screening Pathology (Sloane et al,
1998). High-grade DCIS is composed of cells with pleomorphic
nuclei, which are usually large, show marked variation in size and
shape, have coarse chromatin and prominent nucleoli and are
irregularly spaced. Mitoses are usually frequent and both
individual cell necrosis and phagocytosis may be present. Low-
grade DCIS consists of cells with monomorphic nuclei that are
usually small, spherical and central. Nucleoli are inconspicuous
and the chromatin is uniform. Mitoses are rare, as is individual cell
necrosis. Intermediate grade DCIS is composed of cells that have
intermediate features and cannot readily be assigned to either of
the above categories. There is mild to moderate pleomorphism that
is less than in high-grade lesions, but the monotony of low-grade
DCIS is absent and nucleoli are often present. In lesions where
differing ducts showed variation in nuclear grade, all grades
present were recorded. Architectural pattern was described as
solid, cribriform, micropapillary or intracystic papillary. When
more than one pattern was present, each was recorded. Necrosis
was scored as 0 absent, 1 mild, 2 moderate or 3 marked (usually of
comedo type). Periductal fibrosis and inflammatory reaction were
both scored as 1 absent/mild, 2 moderate or 3 marked. The grade
of recurrent invasive carcinoma was based on the Nottingham
modification of Bloom and Richardson grading (Elston and Ellis,
1991).
RESULTS
The grade of the DCIS in the original lesions is shown in Table 1.
Over 75% of cases were high grade and only eight cases (6.5%) of
pure low-grade DCIS were present in the study.
At first recurrence, 70 (57%) cases recurred as pure DCIS and 52
(43%) contained invasive carcinoma. Of those with invasion, 43
recurred as invasive with an associated in situ component and nine
as invasive without an in situ component identified. One of the
invasive lesions with an in situ component was micro-invasive
(o1mm in maximum dimension) and is not included in any
further analysis of invasive tumours. As shown in Table 1, in the
113 cases in which DCIS was present in the first recurrence, when
the highest DCIS grade of both the first and recurrent lesion were
considered, there was close agreement between the grades
(k¼0.679). The grades were the same in 95 of 113 cases (84%).
The first lesion contained more than one grade of DCIS in 13 cases
and in seven cases there was more than one grade in the second
DCIS (see Table 2). If all grades were considered, there were nine
cases in which the grade of the second DCIS was not seen in the
first lesion. In seven, the grade was lower and in two it was higher.
In all, 19 patients had a second recurrence. In nine of these
patients, both recurrences were pure in situ, in four both contained
in situ and invasive disease, in four the first was pure in situ but
the second contained invasive carcinoma and in two patients,
although invasion was present in the first recurrence, it could not
be identified in the second. Again, there was close agreement
between the grade of the DCIS in the original lesion and the second
recurrence (data not shown).
The majority of the invasive recurrences followed high-grade
DCIS (42 of 55; 76%) and only four occurred in patients in whom
Table 1 Comparison of original and recurrent DCIS grades
Recurrent DCIS grade (highest present)
a
Original DCIS grade
(highest present)
1 2 3 Total
16 1 1 8
2 2 16 2 20
3 1 11 73 85
Total 9 28 76 113
aOnly first recurrence included. w
2¼97.76, Po0.001, k¼0.679.
Table 2 Numbers of cases with mixed DCIS grade
Number of cases with mixed DCIS grades
3+2+1 3+2 3+1 2+1
Original DCIS 1 7 1 4
Recurrent DCIS 1 5 0 1
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agreement between the highest grade of the original DCIS and the
grade of the first detected recurrent invasive tumour, whether this
was in the first or subsequent recurrence (k¼0.241). As shown in
Table 3, in 27 of the 55 cases (49%) the grades were the same, in
the rest the invasive grade was lower in 25 and higher in three. In
21 of the former the DCIS was grade 3, while the invasive
carcinoma was grade 2. Table 4 shows that the DCIS grade of the
recurrent in situ carcinoma associated with the invasive carcinoma
was related to the grade of the invasive carcinoma (k¼0.513). The
grade was the same in 30 of 46 cases (65%). The invasive grade was
higher in two patients and lower in 14. In 11 of the latter the DCIS
was grade 3 and the invasive carcinoma was grade 2.
The different components of the grade of the invasive carcinoma
(tubule formation, nuclear pleomorphism and mitoses) were
analysed separately in relation to the grade of both the original
and the recurrent in situ carcinomas. Fair agreement was found
between the original DCIS grade and the pleomorphism score
(k¼0.396) (Table 5), but not with either tubule formation or the
mitotic score. The recurrent DCIS was related to all the three
components, but most strongly to pleomorphism (k¼0.485)
(Table 6).
As shown in Tables 7 and 8, the scores for necrosis and
inflammatory reaction within the original and recurrent DCIS were
also associated (k¼0.380 and 0.340, respectively). No such
association was found for architectural pattern or periductal
fibrosis. The number of cases with a mixed pattern made analysis
of the former difficult.
In addition (data not shown), high-grade DCIS was associated
with high scores for necrosis, inflammatory reaction and fibrosis,
and also with the presence of a solid growth pattern, either alone,
or in combination with other patterns. High scores for necrosis,
periductal fibrosis and inflammation and the presence of a solid
growth pattern, in the original DCIS, were also associated with
high-grade recurrent DCIS and with the presence of invasion in the
recurrence.
DISCUSSION
This study of tumours from 122 patients who developed relapse of
DCIS or invasive progression shows strong agreement between the
grade of initial DCIS and subsequent recurrent in situ lesions
(k¼0.679). In 84% of cases they were the same. There is also an
association, although less strong, between the grade of initial DCIS
and the grade of subsequent invasive recurrences (k¼0.241).
These findings add strength to the report of similar findings in a
subsection (n¼31) of the cases included in the current study
Table 3 Comparison of original DCIS grade with recurrent invasive
grade
Recurrent invasive grade
a
Original DCIS grade
(highest)
1 2 3 Total
1 2 114
2 3 519
3 1 21 20 42
Total 6 27 22 55
aFirst detected invasive tumour whether in first or second recurrence. w
2¼15.82,
P¼0.003, k¼0.241.
Table 4 Comparison of grades of DCIS and invasive carcinoma in
recurrent lesions
Associated recurrent invasive grade
a
Recurrent DCIS grade
(highest present)
1 2 3 Total
1 3 104
23 8 1 1 2
3 0 11 19 30
Total 6 20 20 46
aFirst detected invasive tumour whether in first or second recurrence. w
2¼26.99,
Po0.001, k¼0.573.
Table 5 Comparison of original DCIS grade with pleomorphism score of
recurrent invasive cancer
Recurrent invasive grade pleomorphism score
a
Original DCIS
grade (highest
present)
1 2 3 Total
11 1 2 4
20 5 4 9
30 6 3 6 4 2
Total 1 12 42 55
aFirst detected invasive carcinoma whether in first or second recurrence. w
2¼21.12,
Po0.001, k¼0.396.
Table 6 Comparison of recurrent DCIS grade with pleomorphism score
of recurrent invasive cancer
Associated recurrent invasive carcinoma
pleomorphism score
a
Recurrent DCIS
grade (highest)
1 2 3 Total
11 3 0 4
20 6 7 1 3
30 3 2 6 2 9
Total 1 12 33 46
aFirst detected invasive carcinoma whether in first or second recurrence. w
2¼23.68,
Po0.001, k¼0.485.
Table 7 Comparison of the presence of necrosis in original and
recurrent DCIS
Necrosis recurrent DCIS
Necrosis original DCIS 0 1 2 3 Total
0 1 5654 3 0
1 8434 1 9
2 1265 1 4
3 4 2 2 16 24
Total 28 14 16 29 87
w
2¼28.04, Po0.001, k¼0.380.
Table 8 Comparison of the degree of inflammation in original and
recurrent DCIS
Inflammation recurrent DCIS
Inflammation original DCIS 1 2 3 Total
13 3 1 5 1 4 9
21 6 9 1 2 6
30 6 6 1 2
Total 49 30 8 87
w
2¼34.26, Po0.001, k¼0.340.
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EORTC study on recurrent lesions from 116 patients (Bijker et al,
2001b). In the latter study, the DCIS was found to be the same in
the 70% of initial and recurrent lesions, and in 53% of cases the
grade of the recurrent invasive carcinoma was the same.
In our study, where the grade of the initial DCIS and that of
either the recurrent DCIS or the recurrent invasive tumour were
not the same, the grade of the subsequent tumour was more often
lower than higher. In a significant number of cases the initial DCIS
grade was 3, whereas the recurrent invasive tumour was grade 2. A
similar association was found with the recurrent DCIS associated
with the invasive carcinoma. This association of grade 3 DCIS with
grade 2 invasive carcinoma has been noted previously (Lampejo
et al, 1994; Barnes et al, 2000). Of more importance was the finding
in one case each of recurrent invasive carcinoma grade 2 and 3
following an initial low-grade DCIS lesion. Conversely, however,
invasive grade 1 carcinomas followed three cases of intermediate
grade DCIS and one of high-grade DCIS.
The criteria used for grading DCIS and invasive carcinomas are
not the same. The grading system for DCIS used in this study was
that used in the UK NHSBSP, which is based only on nuclear
morphology (Sloane et al, 1998). The additional evaluation of
tubule formation and number of mitoses in the grading of invasive
carcinomas may well account for some of the discrepancies
between DCIS grade and that of the invasive tumours. Indeed, a
closer association was found between the nuclear pleomorphism
score for the recurrent invasive carcinoma and the original DCIS
grade (k¼0.396 and 0.485, respectively).
A possible reason for the lack of agreement between the original
and recurrent lesions is that the second lesion is a new primary
tumour rather than a recurrence of the previous one. One way to
try to evaluate this is to see whether or not the lesions arose at the
same site. It was difficult in many cases to ascertain the site of
recurrent lesions in the breast. Where this information could be
found, it was in the same quadrant in the majority of cases
(480%). In the EORTC study, 11% of recurrences occurred in a
different quadrant from the original lesion, but this was not found
to affect the level of agreement (Bijker et al, 2001b).
The EORTC study also evaluated the immunohistochemical
profile of the initial and subsequent DCIS and found 63%
agreement with staining for oestrogen and progesterone receptors,
p53 and HER2/neu oncoprotein (Bijker et al, 2001b). Another
study has looked at the chromosomal alterations of in situ
carcinomas and recurrent lesions using comparative genome
hybridisation (CGH). A high level of agreement in 18 of 20 cases
was found, although the mean number of CGH changes was higher
in the recurrent than the initial lesions (Waldman et al, 2000). Both
of these studies add strength to the theory that the recurrent
lesions following excision of DCIS are closely related to the original
disease and almost certainly represent re-growth of residual
tumour. This emphasises the importance of clear margins at the
time of initial surgery.
The cases for this study were selected on the basis that the DCIS
had recurred and inevitably included a large proportion of high-
grade DCIS and only eight low-grade lesions. Most previous
studies of recurrence following treatment of DCIS have found a
higher incidence of both DCIS and invasive carcinoma following
high-grade DCIS, at least in the short term (Lagios et al, 1989;
Schwartz et al, 1992; Bellamy et al, 1993; Solin et al, 1993; Sneige
et al, 1995; Silverstein et al, 1996; Fisher et al, 1999). In the EORTC
study, although the risk of DCIS recurrence was found to be
significantly related to the initial histology, the risk of invasive
recurrence was not (Bijker et al, 2001a). However, patients with
poorly differentiated DCIS had a significantly higher risk of
developing distant metastases and of death, which must reflect the
higher grade of invasive carcinomas associated with this type of
DCIS. Furthermore, within well-differentiated DCIS, those with a
clinging or micropapillary pattern had significantly lower rates of
recurrence than those with a cribriform pattern.
The findings in the current study that high-grade DCIS is
associated with high scores for periductal necrosis, fibrosis and
inflammatory reaction and with the presence of a solid growth
pattern is to be expected. An association between the scores for
these features in the original DCIS and with the occurrence of
high-grade DCIS or the presence of invasion in recurrent lesions is
also to be anticipated.
The number of cases of recurrent invasive carcinoma in this
study is small, particularly following low-grade DCIS. As recur-
rence following low-grade DCIS may occur long after diagnosis of
the original lesion, long-term follow-up may be necessary to detect
such lesions (Page et al, 1995; Solin et al, 1995). Although this study
shows only fair agreement between the grade of the original DCIS
and that of the subsequent invasive tumour, there is no suggestion
in this or the EORTC study that low-grade lesions often progress to
a higher grade. This is in agreement with the consistency in
malignancy grade, which has been found in studies of primary
invasive mammary carcinoma when compared to both local and
distant recurrences (Hitchcock et al, 1989; Millis et al, 1998).
There is growing evidence that low-grade and high-grade
carcinomas are two distinctly different entities. Immunohisto-
chemical studies of a range of markers show that they have
different profiles. Both in situ and invasive low-grade lesions
express oestrogen and progesterone receptors, but are usually
negative for oncoproteins (HER/neu and p53). High-grade lesions
exhibit the reverse (Hitchcock et al, 1989; Gullick et al, 1991;
Barnes et al, 1993; Millis et al, 1996; Ellis et al, 1999). Molecular
genetic studies find that low-grade lesions often demonstrate 16q
deletions, while high-grade lesions have allelic losses of more
chromosomal areas frequently including 1p, 1q, 6q, 9p, 11p, 13q
and 17q. Intermediate grade DCIS tends to show combinations of
the patterns associated with low- and high-grade lesions (Buerger
et al, 1999a and b; Ellis et al, 1999; Roylance et al, 2002).
This study adds weight to the idea that recurrence following
treatment of DCIS represents re-growth of residual disease. It also
supports the concept that the grade of mammary carcinoma does
not progress with time. Further studies with longer follow-up and, if
possible, greater numbers of low-grade tumours are needed finally to
answer the question. Owing to the natural history of low-grade DCIS,
it may be necessary to combine the results from many centres in
order to obtain sufficient numbers of recurrent lesions for analysis.
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